AI is rewriting the rules of biological experiments, but safety regulations aren’t keeping up

Artificial intelligence is rapidly learning to autonomously design and run biological experiments, but the systems intended to govern those capabilities are struggling to keep pace. AI company OpenAI and biotech company Ginkgo Bioworks announced in February 2026 that OpenAI’s flagship model GPT-5 had autonomously designed and run 36,000 biological experiments. It did this through a robotic cloud laboratory, a facility where automated equipment controlled remotely by computers carries out experiments.